Posted by Michael Wonder on 26 Mar 2019
Numerous G-BA decisions on new medicines - five active substances with considerable added value
22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the added value of new medicines or medicines with new application areas.
Five drugs were the second highest added benefit category "considerable" certified. The evaluation results of the G-BA now form the basis for the negotiations between the GKV Spitzenverband and the pharmaceutical companies on the amount of the reimbursement. A missing additional benefit does not mean a prescription exclusion.
However, in this case it is usually not possible to agree on a higher reimbursement amount than for the comparator therapy.
